Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-05

AUTHORS

Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

ABSTRACT

BACKGROUND: In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy. A statistically significant improvement in overall survival was observed at a second interim analysis with 320 recorded deaths. METHODS: 658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60 mg daily) or everolimus (10 mg daily). Survival follow-up continued to reach the 408 deaths that were pre-specified for the final analysis. RESULTS: With 430 deaths (198 for cabozantinib and 232 for everolimus), median overall survival was 21.4 months with cabozantinib and 17.1 months with everolimus (HR 0.70, 95% CI 0.58-0.85; P = 0.0002). Safety profiles of cabozantinib and everolimus were consistent with those reported previously. CONCLUSIONS: Cabozantinib significantly improved overall survival compared with everolimus in previously treated patients with advanced RCC with consistent results after long-term follow-up. More... »

PAGES

1176-1178

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41416-018-0061-6

DOI

http://dx.doi.org/10.1038/s41416-018-0061-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101747789

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29576624


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, 10075, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Motzer", 
        "givenName": "Robert J.", 
        "id": "sg:person.01234500340.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, 94805, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Mary University of London", 
          "id": "https://www.grid.ac/institutes/grid.4868.2", 
          "name": [
            "Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powles", 
        "givenName": "Thomas", 
        "id": "sg:person.0664224756.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664224756.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Exelixis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428377.d", 
          "name": [
            "Exelixis, Inc, 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scheffold", 
        "givenName": "Christian", 
        "id": "sg:person.01125075530.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125075530.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana-Farber Cancer Institute, 02215, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choueiri", 
        "givenName": "Toni K.", 
        "id": "sg:person.01155331400.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155331400.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1510016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010957301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-11-0264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025899139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-05", 
    "datePublishedReg": "2018-05-01", 
    "description": "BACKGROUND: In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy. A statistically significant improvement in overall survival was observed at a second interim analysis with 320 recorded deaths.\nMETHODS: 658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60\u2009mg daily) or everolimus (10\u2009mg daily). Survival follow-up continued to reach the 408 deaths that were pre-specified for the final analysis.\nRESULTS: With 430 deaths (198 for cabozantinib and 232 for everolimus), median overall survival was 21.4 months with cabozantinib and 17.1 months with everolimus (HR 0.70, 95% CI 0.58-0.85; P\u2009=\u20090.0002). Safety profiles of cabozantinib and everolimus were consistent with those reported previously.\nCONCLUSIONS: Cabozantinib significantly improved overall survival compared with everolimus in previously treated patients with advanced RCC with consistent results after long-term follow-up.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/s41416-018-0061-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "118"
      }
    ], 
    "name": "Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma", 
    "pagination": "1176-1178", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a2be76346eef1c561fbd24b98c20203442e602d8c72eb15e9459fc93cbe1097f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29576624"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41416-018-0061-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101747789"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41416-018-0061-6", 
      "https://app.dimensions.ai/details/publication/pub.1101747789"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000366_0000000366/records_112042_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/s41416-018-0061-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0061-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0061-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0061-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0061-6'


 

This table displays all metadata directly associated to this object as RDF triples.

126 TRIPLES      21 PREDICATES      34 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41416-018-0061-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nf132e755ff13432fa2c046ed9d8e2a26
4 schema:citation https://doi.org/10.1016/j.ejca.2008.10.026
5 https://doi.org/10.1016/s1470-2045(16)30107-3
6 https://doi.org/10.1056/nejmoa1510016
7 https://doi.org/10.1056/nejmoa1510665
8 https://doi.org/10.1158/1535-7163.mct-11-0264
9 schema:datePublished 2018-05
10 schema:datePublishedReg 2018-05-01
11 schema:description BACKGROUND: In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy. A statistically significant improvement in overall survival was observed at a second interim analysis with 320 recorded deaths. METHODS: 658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60 mg daily) or everolimus (10 mg daily). Survival follow-up continued to reach the 408 deaths that were pre-specified for the final analysis. RESULTS: With 430 deaths (198 for cabozantinib and 232 for everolimus), median overall survival was 21.4 months with cabozantinib and 17.1 months with everolimus (HR 0.70, 95% CI 0.58-0.85; P = 0.0002). Safety profiles of cabozantinib and everolimus were consistent with those reported previously. CONCLUSIONS: Cabozantinib significantly improved overall survival compared with everolimus in previously treated patients with advanced RCC with consistent results after long-term follow-up.
12 schema:genre research_article
13 schema:inLanguage en
14 schema:isAccessibleForFree true
15 schema:isPartOf Nabe4ca945f884b77b3468a8b6276ad76
16 Nfef29d06ca724f829762bfb3fe7479a7
17 sg:journal.1017082
18 schema:name Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
19 schema:pagination 1176-1178
20 schema:productId N03476c16678a42f08b48196f9a9ae604
21 N09d83d7c6f524d3e9073833db09f6595
22 N5b105315c73d472baa153cd20163ea8e
23 N788324e8df5c4687865f57e88349350b
24 N816caba908b14f1496b34c6866b03140
25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101747789
26 https://doi.org/10.1038/s41416-018-0061-6
27 schema:sdDatePublished 2019-04-11T13:04
28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
29 schema:sdPublisher N5b1f4078a6b94442bacdb9cc3bc157b9
30 schema:url https://www.nature.com/articles/s41416-018-0061-6
31 sgo:license sg:explorer/license/
32 sgo:sdDataset articles
33 rdf:type schema:ScholarlyArticle
34 N03476c16678a42f08b48196f9a9ae604 schema:name dimensions_id
35 schema:value pub.1101747789
36 rdf:type schema:PropertyValue
37 N09d83d7c6f524d3e9073833db09f6595 schema:name nlm_unique_id
38 schema:value 0370635
39 rdf:type schema:PropertyValue
40 N13bd5eba87b4452ca4aa7e8b3ebc3f53 rdf:first sg:person.01155331400.39
41 rdf:rest rdf:nil
42 N5b105315c73d472baa153cd20163ea8e schema:name pubmed_id
43 schema:value 29576624
44 rdf:type schema:PropertyValue
45 N5b1f4078a6b94442bacdb9cc3bc157b9 schema:name Springer Nature - SN SciGraph project
46 rdf:type schema:Organization
47 N6b2c11b539114d7896729f0a35e9f57f rdf:first sg:person.0664224756.85
48 rdf:rest Nb814bf778f9b47389427d0fd9f6f097b
49 N788324e8df5c4687865f57e88349350b schema:name doi
50 schema:value 10.1038/s41416-018-0061-6
51 rdf:type schema:PropertyValue
52 N816caba908b14f1496b34c6866b03140 schema:name readcube_id
53 schema:value a2be76346eef1c561fbd24b98c20203442e602d8c72eb15e9459fc93cbe1097f
54 rdf:type schema:PropertyValue
55 N9a46e614ba3d43b9a04e381f1f980295 rdf:first sg:person.01304252172.82
56 rdf:rest N6b2c11b539114d7896729f0a35e9f57f
57 Nabe4ca945f884b77b3468a8b6276ad76 schema:issueNumber 9
58 rdf:type schema:PublicationIssue
59 Nb814bf778f9b47389427d0fd9f6f097b rdf:first sg:person.01125075530.70
60 rdf:rest N13bd5eba87b4452ca4aa7e8b3ebc3f53
61 Nf132e755ff13432fa2c046ed9d8e2a26 rdf:first sg:person.01234500340.18
62 rdf:rest N9a46e614ba3d43b9a04e381f1f980295
63 Nfef29d06ca724f829762bfb3fe7479a7 schema:volumeNumber 118
64 rdf:type schema:PublicationVolume
65 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
66 schema:name Medical and Health Sciences
67 rdf:type schema:DefinedTerm
68 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
69 schema:name Clinical Sciences
70 rdf:type schema:DefinedTerm
71 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-018-0061-6
72 rdf:type schema:MonetaryGrant
73 sg:journal.1017082 schema:issn 0007-0920
74 1532-1827
75 schema:name British Journal of Cancer
76 rdf:type schema:Periodical
77 sg:person.01125075530.70 schema:affiliation https://www.grid.ac/institutes/grid.428377.d
78 schema:familyName Scheffold
79 schema:givenName Christian
80 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125075530.70
81 rdf:type schema:Person
82 sg:person.01155331400.39 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
83 schema:familyName Choueiri
84 schema:givenName Toni K.
85 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155331400.39
86 rdf:type schema:Person
87 sg:person.01234500340.18 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
88 schema:familyName Motzer
89 schema:givenName Robert J.
90 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
91 rdf:type schema:Person
92 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
93 schema:familyName Escudier
94 schema:givenName Bernard
95 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
96 rdf:type schema:Person
97 sg:person.0664224756.85 schema:affiliation https://www.grid.ac/institutes/grid.4868.2
98 schema:familyName Powles
99 schema:givenName Thomas
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664224756.85
101 rdf:type schema:Person
102 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1056/nejmoa1510016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010957301
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1158/1535-7163.mct-11-0264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025899139
111 rdf:type schema:CreativeWork
112 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
113 schema:name Institut Gustave Roussy, 94805, Villejuif, France
114 rdf:type schema:Organization
115 https://www.grid.ac/institutes/grid.428377.d schema:alternateName Exelixis (United States)
116 schema:name Exelixis, Inc, 94080, South San Francisco, CA, USA
117 rdf:type schema:Organization
118 https://www.grid.ac/institutes/grid.4868.2 schema:alternateName Queen Mary University of London
119 schema:name Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ, London, UK
120 rdf:type schema:Organization
121 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
122 schema:name Memorial Sloan Kettering Cancer Center, 10075, New York, NY, USA
123 rdf:type schema:Organization
124 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
125 schema:name Dana-Farber Cancer Institute, 02215, Boston, MA, USA
126 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...